Purpose: p27kip1 belongs to the KIP/CIP family of cyclin-dependent kinase inhibitors and is considered to be a tumor suppressor. Involucrin has been known as a marker of differentiation of squamous cell carcinoma (SCC). The aim of this study was to evaluate the clinicopathologic significance of the expression of p27 and involucrin in esophageal SCC. Methods: Immunohistochemical expression of p27 and involucrin was examined in 70 specimens of esophageal SCC. The correlation of the expression of these proteins and clinicopathologic features was evaluated. Results: Cellular differentiation in esophageal SCC was significantly correlated with the expression of p27 and involucrin (p = 0.010 and p = 0.002, respectively). Among well, moderately and poorly differentiated SCCs, 45.8 ± 21.6, 20.0 ± 15.0 and 10.6 ± 9.1% of carcinoma cells expressed involucrin, respectively (p < 0.0001 for well vs. poorly, p < 0.0001 for well vs. moderately, and p = 0.042 for moderately vs. poorly). There existed a more powerful statistical difference regarding the histological grade between SCCs with the expression of both p27 and involucrin and tumors with other expression patterns (p = 0.0001). Conclusions: Expression of both p27 and involucrin can be a powerful biological marker of cellular differentiation of esophageal SCC.

Keywords:
Esophagus, Squamous cell carcinoma, p27, Involucrin, Cellular differentiation
1.
Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 1994;14:3683–3694.
2.
Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW: p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313–323.
3.
Ohtsubo M, Roberts JM: Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993;259:1908–1912.
4.
Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP: p27/Kip1 mutation found in breast cancer. Cancer Res 1996;56:2400–2404.
5.
Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 1996;271:1861–1864.
6.
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231–234.
7.
Slingerland J, Pagano M: Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000;183:10–17.
8.
Migita T, Oda Y, Naito S, Tsuneyoshi M: Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002;94:973–979.
9.
Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD: The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 2005;103:1336–1346.
10.
Anayama T, Furihata M, Ishikawa T, Ohtsuki Y, Ogoshi S: Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma. Int J Cancer 1998;79:439–443.
11.
Shamma A, Doki Y, Tsujinaka T, Shiozaki H, Inoue M, Yano M, Kawanishi K, Monden M: Loss of p27(KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Oncology 2000;58:152–158.
12.
Kagawa Y, Yoshida K, Hirai T, Toge T: Significance of the expression of p27Kip1 in esophageal squamous cell carcinomas. Dis Esophagus 2000;13:179–184.
13.
Shibata H, Matsubara O, Wakiyama H, Tanaka S: The role of cyclin-dependent kinase inhibitor p27 in squamous cell carcinoma of the esophagus. Pathol Res Pract 2001;197:157–164.
14.
Ohbu M, Saegusa M, Okayasu I: Apoptosis and cellular proliferation in oesophageal squamous cell carcinomas: differences between keratinizing and nonkeratinizing types. Virchows Arch 1995;427:271–276.
15.
Nozoe T, Korenaga D, Itoh S, Futatsugi M, Maehara Y: Clinicopathological significance of pRb2/p130 expression in squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol 2002;128:691–696.
16.
Nozoe T, Takahashi I, Baba H, Maehara Y: Relationship between intracellular localization of p34cdc2 protein and differentiation of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2005;131:179–183.
17.
Nozoe T, Ezaki T, Kabashima A, Baba H, Maehara Y: Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. Am J Surg 2005;189:110–115.
18.
Eckert RL, Green H: Structure and evolution of the human involucrin gene. Cell 1986;46:583–589.
19.
Crish JF, Howard JM, Zaim TM, Murthy S, Eckert RL: Tissue-specific and differentiation-appropriate expression of the human involucrin gene in transgenic mice: an abnormal epidermal phenotype. Differentiation 1993;53:191–200.
20.
Takahashi H, Kobayashi H, Matsuo S, Iizuka H: Repression of involucrin gene expression by transcriptional enhancer factor 1 (TEF-1). Arch Dermatol Res 1995;287:740–746.
21.
Rice RH, Green H: Presence in human epidermal cells of a soluble protein precursor of the cross-linked envelope: activation of the cross-linking by calcium ions. Cell 1979;18:681–694.
22.
Banks-Schlegel S, Green H: Involucrin synthesis and tissue assembly by keratinocytes in natural and cultured human epithelia. J Cell Biol 1981;90:732–737.
23.
Japanese Society for Esophageal Diseases: Guidelines for the clinical and pathologic studies on carcinoma of the esophagus, 9th edition: preface, general principles, part I. Esophagus 2004;1:61–88.
24.
Japanese Society for Esophageal Diseases: Guidelines for the clinical and pathologic studies on carcinoma of the esophagus, 9th edition: part II. Esophagus 2004;1:107–125.
25.
Sobin LH, Wittekind C: International Union Against Cancer. TNM Classification of Malignant Tumours, ed 5. New York, Wiley-Liss, 1997, pp 54–58.
26.
Kammerer U, Kapp M, Gassel AM, Richter T, Tank C, Dietl J, Ruck P: A new rapid immunohistochemical staining technique using the EnVision antibody complex. J Histochem Cytochem 2001;49:623–630.
27.
Nita ME, Nagawa H, Tominaga O, Tsuno N, Hatano K, Kitayama J, Tsuruo T, Domene CE, Muto T: p21Waf1/Cip1 expression is a prognostic marker in curatively resected esophageal squamous cell carcinoma, but not p27Kip1, p53, or Rb. Ann Surg Oncol 1999;6:481–488.
28.
Itami A, Shimada Y, Watanabe G, Imamura M: Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology 1999;57:311–317.
29.
Wang QM, Jones JB, Studzinski GP: Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 1996;56:264–267.
30.
Coats S, Flanagan WM, Nourse J, Roberts JM: Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272:877–880.
31.
Walts AE, Said JW, Siegel MB, Banks-Schlegel S: Involucrin, a marker of squamous and urothelial differentiation. An immunohistochemical study on its distribution in normal and neoplastic tissues. J Pathol 1985;145:329–340.
32.
Nair SA, Nair MB, Jayaprakash PG, Rajalekshmy TN, Nair MK, Pillai MR: Involucrin and tumor progression in the uterine cervix. Pathobiology 1996;64:333–338.
33.
van Bommel PF, Kenemans P, Helmerhorst TJ, Gallee MP, Ivanyi D: Expression of cytokeratin 10, 13, and involucrin as prognostic factors in low stage squamous cell carcinoma of the uterine cervix. Cancer 1994;74:2314–2320.
34.
Roland NJ, Rowley H, Scraggs M, Johnson P, Jones AS: MIB-1 and involucrin expression in laryngeal squamous carcinoma: the relationship to host and tumour factors and survival. Clin Otolaryngol Allied Sci 1996;21:429–438.
35.
Kaganoi J, Watanabe G, Okabe M, Nagatani S, Kawabe A, Shimada Y, Imamura M, Sakai Y: STAT1 activation-induced apoptosis of esophageal squamous cell carcinoma cells in vivo. Ann Surg Oncol 2007;14:1405–1415.
36.
Okamura T, Shimada Y, Imamura M, Yasumoto S: Neurotrophin receptor p75(NTR) characterizes human esophageal keratinocyte stem cells in vitro. Oncogene 2003;22:4017–4026.
37.
Fujii T, Kato S, Yamana H, Tanaka Y, Fujita H, Shirouzu K, Morimatsu M: Expression of G1 cell cycle markers and the effect of adenovirus-mediated overexpression of p21Waf-1 in squamous cell carcinoma of the esophagus. Int J Oncol 2001;18:157–163.
38.
Said JW, Nash G, Sassoon AF, Shintaku IP, Banks-Schlegel S: Involucrin in lung tumors. A specific marker for squamous differentiation. Lab Invest 1983;49:563–568.
39.
Suo Z, Holm R, Nesland JM: Squamous cell carcinomas. An immunohistochemical study of cytokeratins and involucrin in primary and metastatic tumours. Histopathology 1993;23:45–54.
© 2006 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.